secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001193125-24-165812
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals stockholders elect three Class I directors, ratify EY as auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Shareholders elected Rajeev Dadoo, Michael Kelly, and Pratik Shah as Class I directors for terms expiring at 2027 annual meeting.
- Proposal to ratify Ernst & Young as independent auditor for FY 2024 passed with over 79.9M votes for, 0.03M against.
- Total shares outstanding and entitled to vote were 96,894,394 as of record date April 24, 2024.
- Broker non-votes were 7.6M to 7.8M on director elections, none on auditor ratification.
- All proposals received significant majority votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524165812/0001193125-24-165812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524165812/d815026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-165812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer